4.8 Review

Complement Activation in Inflammatory Skin Diseases

期刊

FRONTIERS IN IMMUNOLOGY
卷 9, 期 -, 页码 -

出版社

FRONTIERS MEDIA SA
DOI: 10.3389/fimmu.2018.00639

关键词

complement; dermatology; skin diseases; innate immunity; psoriasis; hidradenitis suppurativa; lupus erythematosus; bullous pemphigoid

向作者/读者索取更多资源

The complement system is a fundamental part of the innate immune system, playing a crucial role in host defense against various pathogens, such as bacteria, viruses, and fungi. Activation of complement results in production of several molecules mediating chemotaxis, opsonization, and mast cell degranulation, which can contribute to the elimination of pathogenic organisms and inflammation. Furthermore, the complement system also has regulating properties in inflammatory and immune responses. Complement activity in diseases is rather complex and may involve both aberrant expression of complement and genetic deficiencies of complement components or regulators. The skin represents an active immune organ with complex interactions between cellular components and various mediators. Complement involvement has been associated with several skin diseases, such as psoriasis, lupus erythematosus, cutaneous vasculitis, urticaria, and bullous dermatoses. Several triggers including auto-antibodies and micro-organisms can activate complement, while on the other hand complement deficiencies can contribute to impaired immune complex clearance, leading to disease. This review provides an overview of the role of complement in inflammatory skin diseases and discusses complement factors as potential new targets for therapeutic intervention.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.8
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

Article Dermatology

Mobile e-diary application facilitates the monitoring of patient-reported outcomes and a high treatment adherence for clinical trials in dermatology

M. Rijsbergen, T. Niemeyer-van der Kolk, R. Rijneveld, J. H. F. M. Pinckaers, I Meshcheriakov, J. N. Bouwes Bavinck, M. B. A. van Doorn, G. Hogendoorn, G. Feiss, A. F. Cohen, J. Burggraaf, M. I. E. van Poelgeest, R. Rissmann

JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY (2020)

Article Pharmacology & Pharmacy

Results of phase 2 trials exploring the safety and efficacy of omiganan in patients with human papillomavirus-induced genital lesions

Melanie Rijsbergen, Rianne Rijneveld, Marina Todd, Gary L. Feiss, Stijn T. P. Kouwenhoven, Koen D. Quint, Dirk C. J. G. van Alewijk, Maurits N. C. de Koning, Erica S. Klaassen, Jacobus Burggraaf, Robert Rissmann, Mariette I. E. van Poelgeest

BRITISH JOURNAL OF CLINICAL PHARMACOLOGY (2020)

Article Dermatology

Trichoblastic carcinosarcoma with panfollicular differentiation (panfollicular carcinosarcoma) andCTNNB1(beta-catenin) mutation

Jenny Giang, Asok Biswas, Antien L. Mooyaart, Floris H. Groenendijk, Petra Dikrama, Jeffrey Damman

Summary: This case report presents a rare trichoblastic carcinosarcoma with panfollicular differentiation, with molecular analysis revealing identical molecular aberrations in both epithelial and mesenchymal components. This is the first report of panfollicular carcinosarcoma and the presence of a CTNNB1 mutation in trichoblastic carcinosarcoma.

JOURNAL OF CUTANEOUS PATHOLOGY (2021)

Article Pharmacology & Pharmacy

A randomized controlled trial with a delayed-type hypersensitivity model using keyhole limpet haemocyanin to evaluate adaptive immune responses in man

Mahdi Saghari, Pim Gal, Dimitrios Ziagkos, Jacobus Burggraaf, John F. Powell, Nuala Brennan, Robert Rissmann, Martijn B. A. van Doorn, Matthijs Moerland

Summary: The study demonstrated an increase in anti-KLH antibodies after KLH immunization and a delayed-type hypersensitivity response after intradermal KLH administration. This suggests that the KLH model could serve as an objective tool for studying the pharmacodynamics of T-cell-directed immunomodulatory drugs.

BRITISH JOURNAL OF CLINICAL PHARMACOLOGY (2021)

Article Dermatology

Topical antimicrobial peptide omiganan recovers cutaneous dysbiosis but does not improve clinical symptoms in patients with mild to moderate atopic dermatitis in a phase 2 randomized controlled trial

Tessa Niemeyer-van der Kolk, Thomas P. Buters, Lara Krouwels, Jiry Boltjes, Marieke L. de Kam, Hein van der Wall, Dirk C. J. G. van Alewijk, Ellen H. A. van den Munckhof, Martin J. Becker, Gary Feiss, Edwin F. Florencia, Errol P. Prens, Matthijs Moerland, Jacobus Burggraaf, Robert Rissmann, Martijn B. A. van Doorn

Summary: Omiganan restored dysbiosis by reducing Staphylococcus abundance and increasing diversity. However, there was no significant clinical improvement observed.

JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY (2022)

Article Pharmacology & Pharmacy

Comprehensive evaluation of microneedle-based intradermal adalimumab delivery vs. subcutaneous administration: results of a randomized controlled clinical trial

Justin Jacobse, Wouter ten Voorde, Anushka Tandon, Stefan G. Romeijn, Hendrika W. Grievink, Koen van der Maaden, Michiel J. van Esdonk, Dirk Jan A. R. Moes, Floris Loeff, Karien Bloem, Annick de Vries, Theo Rispens, Gertjan Wolbink, Marieke de Kam, Dimitrios Ziagkos, Matthijs Moerland, Wim Jiskoot, Joke Bouwstra, Jacobus Burggraaf, Lenneke Schrier, Robert Rissmann, Rebecca ten Cate

Summary: This study evaluated the feasibility of intradermal administration of adalimumab using hollow microneedles. It was found that intradermal adalimumab injection was perceived as more painful compared to subcutaneous administration, but resulted in higher relative bioavailability and skin reactions. The study also showed similar safety and pharmacokinetic effects between intradermal and subcutaneous administration routes.

BRITISH JOURNAL OF CLINICAL PHARMACOLOGY (2021)

Editorial Material Pharmacology & Pharmacy

Commentary on Investigator brochures for phase I/II trials lack information on the robustness of preclinical safety studies by Sievers et al.

Robert Rissmann, Rob Zuiker

BRITISH JOURNAL OF CLINICAL PHARMACOLOGY (2021)

Article Pharmacology & Pharmacy

Intradermal lipopolysaccharide challenge as an acute in vivo inflammatory model in healthy volunteers

Thomas P. Buters, Pieter W. Hameeteman, Iris M. E. Jansen, Floris C. van Hindevoort, Wouter Ten Voorde, Edwin Florencia, Michelle Osse, Marieke L. de Kam, Hendrika W. Grievink, Mascha Schoonakker, Amit A. Patel, Simon Yona, Derek W. Gilroy, Erik Lubberts, Jeffrey Damman, Gary Feiss, Robert Rissmann, Manon A. A. Jansen, Jacobus Burggraaf, Matthijs Moerland

Summary: This study aimed to characterize the intradermal LPS response in healthy volunteers as a local inflammation model for clinical pharmacology studies. Results showed that intradermal LPS administration induced a visible response, with acute interleukin and tumor necrosis factor protein response followed by different cellular responses. The study suggests that intradermal LPS administration may be a valuable inflammation model for evaluating the pharmacological activity of anti-inflammatory compounds.

BRITISH JOURNAL OF CLINICAL PHARMACOLOGY (2022)

Article Pharmacology & Pharmacy

Clinical, Cellular, and Molecular Effects of Corticosteroids on the Response to Intradermal Lipopolysaccharide Administration in Healthy Volunteers

Thomas P. Buters, Pieter Hameeteman, Iris M. E. Jansen, Floris C. van Hindevoort, Wouter ten Voorde, Hendrika W. Grievink, Mascha Schoonakker, Marieke L. de Kam, Derek W. Gilroy, Gary Feiss, Robert Rissmann, Manon A. A. Jansen, Jacobus Burggraaf, Matthijs Moerland

Summary: In this study, the inhibitory effects of oral and topical corticosteroid treatment on intradermal lipopolysaccharide (LPS) responses were evaluated. The results showed that corticosteroids significantly suppressed the clinical inflammatory response and reduced the secretion of inflammatory mediators. This experimental model is effective in evaluating the effects of anti-inflammatory drugs.

CLINICAL PHARMACOLOGY & THERAPEUTICS (2022)

Article Pharmacology & Pharmacy

OX40L Inhibition Suppresses KLH-driven Immune Responses in Healthy Volunteers: A Randomized Controlled Trial Demonstrating Proof-of-Pharmacology for KY1005

Mahdi Saghari, Pim Gal, Sally Gilbert, Martin Yateman, Ben Porter-Brown, Nuala Brennan, Sonia Quaratino, Rosamund Wilson, Hendrika W. Grievink, Erica S. Klaassen, Kirsten R. Bergmann, Jacobus Burggraaf, Martijn B. A. van Doorn, John Powell, Matthijs Moerland, Robert Rissmann

Summary: The safety, tolerability, immunogenicity, and pharmacokinetic profile of anti-OX40L monoclonal antibody KY1005 were evaluated, and its effects on antibody response and skin response were observed. The study found that KY1005 demonstrated an acceptable safety and tolerability profile, showed pharmacological activity, and had potential as a novel pharmacological treatment for immune-mediated disorders.

CLINICAL PHARMACOLOGY & THERAPEUTICS (2022)

Article Oncology

Integrin αvβ6 as a Target for Tumor-Specific Imaging of Vulvar Squamous Cell Carcinoma and Adjacent Premalignant Lesions

Bertine W. Huisman, Merve Cankat, Tjalling Bosse, Alexander L. Vahrmeijer, Robert Rissmann, Jacobus Burggraaf, Cornelis F. M. Sier, Mariette I. E. van Poelgeest

Summary: Fluorescence-guided surgery using integrin alpha v beta 6 as a target showed robust discrimination of vulvar tumors and surrounding tissue, suggesting its potential utility in future studies. Immunohistochemistry of membrane proteins identified possible tracers for fluorescence-guided surgery in vulvar (pre)malignancies, emphasizing the need for further evaluation of alpha v beta 6 as a target.

CANCERS (2021)

Review Microbiology

The Human Vulvar Microbiome: A Systematic Review

Lisa Pagan, Roos A. M. Ederveen, Bertine W. Huisman, Jan W. Schoones, Romy D. Zwittink, Frank H. J. Schuren, Robert Rissmann, Jurgen M. J. Piek, Mariette I. E. van Poelgeest

Summary: This systematic review explores the relationship between microbiome and vulvar (pre)malignant disease, revealing differences in vulvar microbiome composition between healthy and diseased states. Although promising, there is limited data with low evidence levels.

MICROORGANISMS (2021)

Review Pharmacology & Pharmacy

A systematic review on disease-drug-drug interactions with immunomodulating drugs: A critical appraisal of risk assessment and drug labelling

Laura M. de Jong, Sylvia D. Klomp, Nicoline Treijtel, Robert Rissmann, Jesse J. Swen, Martijn L. Manson

Summary: This systematic review aimed to evaluate the risk of disease-drug-drug interactions (DDDIs) caused by immunomodulating drugs and summarize the relevant information in FDA/EMA approved drug labeling. The results showed that the DDDI risk of immunomodulating drugs is specific to target and disease.

BRITISH JOURNAL OF CLINICAL PHARMACOLOGY (2022)

Editorial Material Dermatology

Anti-interleukin-17A for pityriasis rubra pilaris: catching the psoriasis biologic wave

Deepak M. W. Balak, Robert Rissmann

BRITISH JOURNAL OF DERMATOLOGY (2022)

Letter Dermatology

No effect of topical digoxin and furosemide for patients with actinic keratosis

Bertine W. Huisman, Lauren E. H. Nene, Feeke L. L. Linders, Tom K. Gambrah, Tessa Niemeyer van Der Kolk, Marieke L. de Kam, Jan Nico Bouwes Bavinck, Jacobus Burggraaf, Gary Feiss, Robert Rissmann

JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY (2023)

暂无数据